Navigation Links
CardioDynamics Reports Eighth Consecutive Quarterly Revenue Increase Over Prior Year and 12% Revenue Growth in 2008
Date:2/5/2009

Achieves Positive Operating Cash Flow in Fourth Quarter

SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ -- CardioDynamics (Nasdaq: CDIC), the innovator and leader of BioZ(R) Impedance Cardiography (ICG) technology, today reported financial results for its fourth quarter and fiscal 2008.

Key Financial and Operating Results for Fourth Quarter 2008 Compared with Fourth Quarter 2007

  • Net ICG sales increased 6% to $6.5 million, up from $6.2 million
  • ICG sensor revenue increased 11% to $1.9 million, or 29% of total sales, up from $1.7 million
  • ICG monitor and module sales increased 32% to 291 units, 108 of which were BioZ Dx systems, 9 BioZ monitors, 21 Medis monitors and 153 BioZ modules, up from a total of 221 ICG monitors and modules
  • ICG gross profit margin was 71%, up from 65%
  • Operating loss was $0.4 million, down from $0.8 million, an improvement of 47%
  • $276,000 of cash flow generated from operations compared with a $234,000 operating cash use

Key Financial and Operating Results of Fiscal 2008 Compared with Fiscal 2007

  • Net ICG sales increased 12% to $24.5 million, up from $21.9 million
  • International sales increased 73% to $4.7 million, up from $2.7 million
  • 994 ICG monitors and modules sold, up 32% from 752, now with over 8,700 ICG monitors and modules sold to date
  • ICG gross profit margin was 72%, up from 68%
  • Operating loss improved 58% to $2.0 million, down from an operating loss of $4.8 million which includes $1.0 million of non-cash charges for depreciation, amortization and equity compensation in 2008, and $0.9 million in 2007

'/>"/>
SOURCE CardioDynamics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. CardioDynamics Announces Investors Retain $5.25 Million 8% Convertible Debt Securities
2. CardioDynamics Reports Second Fiscal Quarter 2008 Results, 18% Revenue Increase for First Half 2008
3. CardioDynamics Announces Second Quarter 2008 Conference Call and Webcast
4. CardioDynamics Announces Significant ICG Study with Nearly Three Times the National Average Blood Pressure Control Rates at the American Society for Hypertension Annual Scientific Meeting
5. CardioDynamics Reports 22% Revenue Growth in First Quarter 2008
6. CardioDynamics Board of Directors Proposes Reverse Split 1:7 of Companys Shares
7. CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007
8. CardioDynamics Announces Strategic Alliance With Leading Medical Equipment Manufacturer in India
9. CardioDynamics Announces Third Quarter 2007 Conference Call and Webcast
10. Cepheid Reports Fourth Quarter and Full Year 2008 Results
11. Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Comparemedicalinsurance.info has released a new blog ... who have health problems. , A pre-existing medical ... clients. No medical exam life insurance plans offer a ... a lot easier. , No medical exam life ... temporary protection, while others will insure the client for ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Discount-Dress.com, an ... and women’s special occasion outfits, is doing its best ... its dresses at discounted rates, up to 75% off. ... new blog . Also, it has unveiled many ... cocktail party dresses, gorgeous lace wedding dresses, purple prom ...
(Date:7/24/2014)... July 24, 2014 Follow ... a rapidly expanding sector in the in-vitro diagnostics ... collection devices, new detection technologies, computers, and automation ... versatility, and speed. In addition to disease diagnosis, ... benefits in patient stratification, drug regimen selection, therapeutic ...
(Date:7/24/2014)... Hanover, MA (PRWEB) July 24, 2014 ... Foundation will be on hand to provide educational and ... 11th Annual Meeting next week in Colorado Springs. , ... from some of the most renowned neurointerventional research ... problem solving and innovating together (with or at) symposiums, ...
(Date:7/24/2014)... July 24, 2014 “To care for him ... and his orphan.” The inspired quote is attributed to Abraham ... of Veterans Affairs (VA). And yet the reality of Lincoln’s ... in exchange for their service in times of conflict, leaves ... represents many veterans locked in a battle they never expected ...
Breaking Medicine News(10 mins):Health News:Life Insurance Without Examinations for Clients Who Have Pre-Existing Medical Conditions 2Health News:Discount-Dress.com Announces the Launch of Its New Blog and Publishes Articles About Its Fabulous Special Occasion Dresses 2Health News:Increasing Molecular Level Understanding of Disease State & Metabolism Drives the Molecular Diagnostics Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Increasing Molecular Level Understanding of Disease State & Metabolism Drives the Molecular Diagnostics Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Increasing Molecular Level Understanding of Disease State & Metabolism Drives the Molecular Diagnostics Market, According to New Report by Global Industry Analysts, Inc. 4Health News:Brain Aneurysm Foundation Provides Key Support to NeuroIntervential Physicians 2Health News:LawyersandSettlements.com Interviews Veterans Benefits Attorney Shanin Specter about Recent VA Hospital Reports 2Health News:LawyersandSettlements.com Interviews Veterans Benefits Attorney Shanin Specter about Recent VA Hospital Reports 3Health News:LawyersandSettlements.com Interviews Veterans Benefits Attorney Shanin Specter about Recent VA Hospital Reports 4Health News:LawyersandSettlements.com Interviews Veterans Benefits Attorney Shanin Specter about Recent VA Hospital Reports 5
... 19 DaVita Inc., a,leading provider of kidney ... (CKD) and kidney failure, today announced that they ... patients,against influenza (flu). Today,s announcement highlights DaVita,s proven ... services, setting the standard for,superior clinical care. , ...
... Lecture for Healthcare ProfessionalsVOORHEES, N.J., Jan. 19 ... being seen in older adults, especially among residents ... complicated by the emergence of a virulent strain ... rates of morbidity and mortality. Implementing strategies for ...
... Center invites women of all ages to attend Girls, ... 6:00 p.m. at Northgate Mall. The event, sponsored by ... more. The Northwest Hospital booth will feature free ... well as body mass index (BMI) and waist measurement ...
... Educational CD provides veterinarians with a new way to understanding and ... ... January 19, 2009 -- Merial today announced the availability of an ... the complex subject of heartworm prevention and treatment in dogs. Launched ...
... Inc., a world leader in handheld x-ray technologies, announced ... patent for its NOMAD Handheld X-ray System. The latest ... having all components of the x-ray system in the ... the world,s first handheld x-ray system. Aribex was previously ...
... Fla., Jan. 19 As the unemployment rate grows, ... who are coping with the,loss of health insurance. COBRA ... but while many workers have the right to,purchase such ... cost is,often prohibitively high. A November 2008 study by ...
Cached Medicine News:Health News:DaVita 'Flu Fighter Program' Vaccinates 85 Percent of Patients 2Health News:Clostridium difficile Infection in Long-Term Care: Tailored Approaches to Management 2Health News:Northwest Hospital Sponsors Girls' Day Out Event at Northgate Mall 2Health News:Heartworm CD by Merial Offers Unique Approach to Managing this Deadly Condition 2Health News:Heartworm CD by Merial Offers Unique Approach to Managing this Deadly Condition 3Health News:Aribex(R) Awarded Patents for Handheld X-ray 2Health News:Is Your Business Ready for the COBRA Premium Subsidy? 2
(Date:7/24/2014)... DALLAS , July 24, 2014  Market ... of IVD Insights™ LabFile , a data ... the US clinical laboratory universe and identifying target ... is a proprietary database that provides IVD manufacturers ... clinical tests, relying on clear and consistent definitions ...
(Date:7/24/2014)... 24, 2014 HIGHLIGHTS:Q2 2014 Results (all ... , Reported sales increased 3% to $701 million.  Sales grew ... added one percentage point to sales growth. , By ... in Applied and 1% in SAFC Commercial. , Reported ... an increase of 13%.  Adjusted diluted EPS in Q2 2014 ...
(Date:7/24/2014)... DIEGO , July 24, 2014   ... announced today a co-promotion agreement with Illumina to ... genome sequence data for precision medicine and clinical ... pharmaceutical companies, through Illumina,s sales force, a solution ... platform for data analytics and storage, and Cypher ...
Breaking Medicine Technology:MDxI Launches Data Resource Setting New Standard for Defining and Targeting US Clinical Laboratory Universe 2Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 2Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 3Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 4Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 5Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 6Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 7Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 8Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 9Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 10Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 11Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 12Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 13Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 14Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 15Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 16Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 17Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 18Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 19Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 20Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 21Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 22Cypher Genomics and Illumina Enter Agreement to Facilitate Genomic Biomarker Discovery 2Cypher Genomics and Illumina Enter Agreement to Facilitate Genomic Biomarker Discovery 3
... Alpharma Inc.,(NYSE: ALO ), a ... its Phase III pivotal efficacy trial that ... naltrexone,hydrochloride) capsules provided significant pain relief in ... osteoarthritis of the hip or knee compared,to ...
... Ardea Biosciences, Inc.,(Nasdaq: RDEA ) today announced ... mitogen-activated ERK kinase (MEK) inhibitor, RDEA119,at the American College ... & Convention Center in Orlando., ... October 7, 2008 from 10:30 a.m. - 4:00 p.m. ...
Cached Medicine Technology:Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 2Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 3Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 4Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 5Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting 2
... 2000 Pipette is a synonym for pipetting ... robust design, and superior operating comfort. Its ... the measuring stroke and blow-out as well ... system ensures utmost accuracy and precision. Ejection ...
25L...
This fixed-volume digital micropipet is used to accurately measure and transfer 50 microliters of solution....
50L...
Medicine Products: